In a single institutional retrospective study by the same group, 39 consecutive patients with pathologically confirmed stage IIIA-B ALK-rearranged NSCLC and treated with either neoadjuvant crizotinib or alectinib were evaluated. Here, ALK is linked to non-small cell lung carcinoma.